Rapid resistome mapping using nanopore sequencing

Eric van der Helm[1], Lejla Imamovic[1], Mostafa M Hashim Ellabaan[1], Willem van Schaik[2], Anna Koza[1] and Morten O.A. Sommer[1,#]

[1] Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, DK-2870 Hørsholm, Denmark

[2] Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands

correspondence should be addressed to M.O.A.S.: msom@bio.dtu.dk

Abstract

The emergence of antibiotic resistance in human pathogens has become a major threat to modern medicine and in particular hospitalized patients. The outcome of antibiotic treatment can be affected by the composition of the gut resistome either by enabling resistance gene acquisition of infecting pathogens or by modulating the collateral effects of antibiotic treatment on the commensal microbiome. Accordingly, knowledge of the gut resistome composition could enable more effective and individualized treatment of bacterial infections. Yet, rapid workflows for resistome characterization are lacking. To address this challenge we developed the poreFUME workflow that deploys functional metagenomic selections and nanopore sequencing to resistome mapping. We demonstrate the approach by functionally characterizing the gut resistome of an ICU patient. The accuracy of the poreFUME pipeline is >97 % sufficient for the reliable annotation of antibiotic resistance genes. The poreFUME pipeline provides a promising approach for efficient resistome profiling that could inform antibiotic treatment decisions in the future.

Keywords

Nanopore sequencing, MinION, resistome, functional metagenomics

Background

It is estimated that every year 700,000 people die of resistant infections [1]. Antibiotic resistance by human pathogens has become a major threat, in particular for hospitalized patients [1, 2]. Bacterial infections by resistant pathogens are also coupled with an increase in healthcare costs[3]. The gut microbiome comprises a diverse set of antibiotic resistance genes which may impact antibiotic treatment

outcomes in at least two ways[4–6]. First, the gut microbiome can act as a reservoir of resistance genes that can be acquired by infecting human pathogens leading to evolution of resistance during infection. Indeed, a close evolutionary relationship between resistance genes in pathogens and commensals has been found [7]. Second, the gut resistome impacts the extent to which the commensal microbiota is affected by antibiotic treatment. Studies of preterm infants and their response to antibiotic treatment suggest that the collateral damage to the commensal microbiota can be predicted from the resistome status at the start of treatment[8]. Accordingly, there is an increasing interest in the development of clinically applicable workflows that enable expedited and comprehensive characterization of the gut resistome. Unfortunately, given the diversity of antibiotic resistance genes in the gut microbiota, sequencing based methods alone cannot enable a representative characterization of the gut resistome. Instead, functional metagenomic selections, which circumvent the culturing step of individual gut microbes, allow less biased interrogation of the gut resistome[9]. Consequently, rapid resistome profiling using a functional-metagenomic approach would be a viable approach to guide personalized antibiotic treatment.

A functional metagenomic workflow consists of several steps, of which the final step is the analysis of metagenomic sequencing data (Figure 1)[10]. Traditionally, sequencing data was obtained using Sanger sequencing, [11, 12], yet, other high-throughput sequencing technologies such as 454 pyrosequencing [13] and Illumina sequencing [6, 14] have been applied to analyze functional metagenomic assays as well. The PARFuMS pipeline based on Illumina data was used to profile the antibiotic resistome of soil and of the human microbiome[4, 6, 14], and PacBio SMRT data has been used to sequence large metagenomic insert libraries (~40 kb) from fosmids [15].

50 There are several challenges related to data processing and annotation in functional
51 metagenomic selections. For Sanger sequencing, the data annotation is usually done
52 on non-complete contigs. In each Sanger set, contigs can be closed by using primer
53 walking. However, primer walking is hardly feasible for high-throughputs datasets
54 and requires weeks to complete. Short read sequencing based on the Illumina platform
55 offers a high-throughput method, yet, contig assembly can be hampered by repetitive
56 sequences in the original insert. A workflow based on PacBio SMRT data
57 circumvents such assembly challenges; however, this technology has a significant
58 capital cost requirement, a large laboratory footprint and is technically demanding
59 limiting point of care applications [16]. In contrast, nanopore sequencing may be able
60 to address these challenges enabling on site monitoring of resistomes in both clinical
61 and environmental settings.
62
63 Nanopore sequencing works by threading a DNA molecule through a nanopore
64 embedded in a membrane. When a voltage is applied over the membrane, an ion
65 current is established and this current is modulated when DNA bases pass through the
66 pore. This current-signal depends on the identity of the base that resides in the pore
67 and is, converted into a nucleotide sequence by downstream software. Using the
68 MinION read lengths larger than 100 kb have been reported [17]. The MinION has
69 already been applied to study various aspects related to antibiotic resistance and
70 infection microbiology, including determining the structure and chromosomal
71 insertion site of a bacterial antibiotic resistance island in *Salmonella* Typhi[16],
72 detection of carbapenemases and ESBL genes as well as their position in Gram-
73 negative pathogenic isolates[18] [19], and identification of species and resistance
74 profiles of *Staphylococcus aureus* and *Mycobacterium tuberculosis* isolates[20]. Yet,

nanopore sequencing has so far not been applied to profile the resistome of a complex microbial community.

In this study we developed the poreFUME workflow to characterize the resistome of a clinical samples (Figure 1) using nanopore sequencing. Metagenomic expression libraries were constructed using fecal samples from a hospitalized patient as input. The libraries were selected on solid media containing various antibiotics and DNA was extracted from the surviving clones expressing metagenomic inserts conferring antibiotic resistance. The extracted DNA was sequenced using nanopore sequencing. Finally the sequence data was processed using the poreFUME computational pipeline which demultiplexes the barcodes, increases the data quality and annotates antibiotic resistance genes.



Figure 1: Overview of the poreFUME workflow consisting of the construction and sequencing of a metagenomic library. Fecal DNA is extracted, purified, fragmented and cloned into a shuttle vector. The library of plasmids is transformed in an *E. coli* expression host and grown on selective media supplemented with antibiotics, this process takes approximately 24 hours. The next day, DNA of the resulting colonies is extracted and barcodes are ligated using a PCR reaction. The PCR amplified DNA is used as input for the sequencing library process which takes 2 hours. The sequencing library is loaded into the MinION nanopore sequencer and run between 6 and 48 hours. Finally, the obtained sequencing data is demultiplexed, error corrected[21] **and annotated using the CARD database**[22] **in the poreFUME pipeline.**

Results

We constructed a metagenomic expression libraries from fecal samples obtained from an Intensive Care Unit (ICU) patient as described in [23] (Materials and methods). The library size ranged between 2.9 – 8.8 x 10^8 bp of DNA (Supplementary table 1). The metagenomic libraries were plated on solid agar media containing inhibitory

103 concentrations of the antibiotics: tobramycin, spectinomycin, ampicillin, cefotaxime,
104 azithromycin, tetracycline or fosfomycin (Supplementary table 2). Clones from the
105 metagenomic libraries able to tolerate each of these seven different antibiotics were
106 detected in all libraries (Supplementary table 2). From each antibiotic plate a
107 representative number of clones were selected (in total 864), pooled, barcoded using
108 PCR and prepared for sequencing using the MinION nanopore sequencer (Materials
109 and methods).
110
111 Nanopore sequencing yielded 95.1 Mbase in 62,890 high-quality 'passing filter' two-
112 direction (2D) reads with a mean length of 1,513 bp (library A)(Supplementary Figure
113 1). As an internal control we multiplexed the sequencing library with 8 other
114 unrelated samples (library B). Due to multiplexing with unrelated samples library B
115 generated only 4,959 sample specific 2D reads (Supplementary table 3). The subsequent
116 part of this study focuses exclusively on the use of high-quality 'passing filter' two-
117 direction (2D) reads.
118
119 The first step of poreFUME is to demultiplex the barcodes. We identified all the 39
120 experimentally attached barcodes in both the nanopore sequencing libraries (Figure 2).
121 The abundance showed a significant correlation of log transformed abundance with
122 the Pearson correlation test ($R^2 = 0.75$, $p < 10^{-12}$) between the two libraries,
123 highlighting the reproducibility of the sequencing and barcode demultiplexing step.
124 Due to the smaller library size of nanopore library B the remainder of this study
125 focuses on library A.



Figure 2: Barcode distribution of the 24,126 2D-reads nanopore library A (green) and control library B (3,361 2D-reads, orange). The Pearson correlation test ($R^2 = 0.75$, $p < 10^{-12}$) shows the significance of the log transformed abundance relationship between the two nanopore libraries.

The sequencing data obtained with MinION nanopore R7 chemistry has an 2D read accuracy of ~85% [21]. This relative high error rate can be mitigated using error correction, with tools such as nanocorrect [21]. Nanocorrect is implemented as second step in the poreFUME pipeline. Nanocorrect has been applied previously to increase the nanopore read accuracy from 80.5% to 95.9% [21]. The algorithm identifies overlapping reads using DALIGNER [24] and calculates a consensus sequence, using partial-order alignment (POA) software [25]. Two rounds of error correction where conducted by the poreFUME pipeline.

We annotated the error corrected sequencing data for the presence of antibiotic resistance genes using Comprehensive Antibiotic Research Database (CARD)[22]. Using the CARD database, 26 different antibiotic resistance genes were identified in the nanopore data set (Figure 4). A variety of antibiotic resistance genes were detected with a mean sequence identity of 97.1%, including beta lactamase genes (*CTX*, *TEM* and *CblA*), genes coding aminoglycoside modifying proteins (from different subclasses of AAC, ANT and APH enzymes) and diverse genes encoding ribosomal and efflux mediated resistance towards tetracycline antibiotic, among others (Figure 3 and S3).

To validate the nanopore sequencing results, we sequenced the same barcoded DNA using PacBio SMRT technology yielding 93.5 Mbase of DNA in 68,144 reads (with

151 >99% accuracy) from two sequencing cells. After annotation with the CARD
152 database, we observed that the exact same set of 26 antibiotic resistance genes
153 detected in the nanopore dataset were also present in the PacBio dataset (Figure 4).
154 The mean sequence identity of the genes identified in the CARD database is for the
155 PacBio dataset with 97.8% slightly better then that of the nanopore dataset with
156 97.2% (Supplementary Figure 2). The abundance of reads between the nanopore and
157 PacBio dataset was in good agreement as calculated using the Pearson correlation test (R^2 =
158 0.71, $p < 10^{-7}$) (Figure 3).



159
160 **Figure 3: Distribution of the occurrence of the 26 different CARD genes found in the PacBio and nanopore**
161 **dataset. The Pearson correlation test (R^2 = 0.71, $p < 10^{-7}$) showed a significant relationship between the**
162 **nanopore and PacBio dataset as assessed by the log-transformed proportion of CARD hits found. Threshold**
163 **for CARD identification are gene coverage of >50% and >80% sequence identity.**



Figure 4: Abundance of 26 CARD genes in the PacBio (blue) and nanopore (green) dataset as show as fraction of the total reads contained in each dataset. The threshold for CARD identification are a gene coverage of >50% and >80% sequence identity.

To further test the accuracy of our nanopore data set we sequenced the selected libraries using Sanger sequencing. The sequence identity between the Sanger reads and the non-corrected 2D reads of nanopore library A was 85.8% (Supplementary Figure 2), this confirms the higher error rate of the used MinION reads [16, 21].

172 However by using two rounds of error correction implemented by poreFUME the
173 sequence identity of the nanopore reads was improved from 86.8% to 97.8%, which
174 enables accurate resistome mapping using CARD.



175

176 **Figure 5: Histogram of the sequence identity of the 2D nanopore sequence reads of library A (12,820 reads)**
177 **after two rounds of error correction, showing a mean sequence identity to the Sanger data set of 97.8%. The**
178 **PacBio dataset after a single round of consensus calling using pbdagcon (3,086 reads) shows a mean**
179 **sequence identity to the Sanger dataset of 99.3%**

180

181 Nanopore reads are longer and typically capture the entire metagenomic insert. In this
182 way analysis of the context of the antibiotic resistance gene is simplified. As an
183 example to link genotype and phenotype we investigated the 244 nanopore reads that
184 were selected on plates containing spectinomycin and resulted in a CARD annotation.
185 All the 244 reads contain the *aadA* gene which encodes an aminoglycoside
186 nucleotidyltransferase known to confer resistance to spectinomycin (Figure 6a). In 74
187 reads *aadA* was flanked by *sat-1* which encodes a streptothricin acetyltransferase and
188 confers resistance to streptothricin, again *sat-1* is likely to be co-selected with *aadA*.
189 In 44 reads the *aadA* was the only gene detected, however in 126 reads *aadA* was
190 flanked by *dfrA1*. The *dfrA1* gene confers resistance to trimethoprim and is not known
191 to confer resistance to spectinomycin. Alignment of the longest nanopore read
192 containing both *dfrA1* and *aadA* against the NT database showed that the two highest
193 scoring hits are part of an integron class I (Figure 6b). Nanopore sequencing is thus
194 able to identify such differing contexts of antibiotic resistance genes, which can
195 impact the probability of a pathogen to acquire specific antibiotic resistance
196 genes[26].



Figure 6a: Example of CARD genes found in the nanopore dataset that were plated on spectinomycin. Of the 244 nanopore reads that were recovered on spectinomycin, all contain the *aadA* which is an aminoglycoside nucleotidyltransferase known to confer resistance to spectinomycin. In 126 reads *aadA* is flanked by *dfrA1* which confers resistance to trimethoprim and in 74 reads *aadA* is flanked by *sat-1* which confers resistance to streptothricin. The genes *sat-1* and *dfrA1* that do not confer known resistance to spectinomycin are thus co-selected with *aadA*. b: **Alignment against the NT database of the longest corrected nanopore read of the 126 reads containing *aadA* and *dfrA* obtained from functional selection on spectinomycin. The corrected nanopore read shares 99% sequence identify with the two top scoring hits in the NT database: (light gray) the class I integron from *Salmonella enterica* subsp. enterica serovar (genbank: HQ132378.1) and the *E. coli* plasmid pH1038-142 (genbank: KJ484634) described by Wang et al.**[27]**. *IntI* denotes integron class I, *IS440* an transposon, *dfrA* encodes a dihydrofolate reductase known to confer resistance against trimethoprim and aadA is an aminoglycoside nucleotidyltransferase known to confer resistance to spectinomycin**

Discussion & Conclusion

Hospital settings, including ICUs, are hotspots for the emergence and selection for antibiotic resistant organisms. In this study we successfully applied nanopore sequencing to characterize the gut resistome of an ICU patient using metagenomic functional selections. Nanopore sequencing is known to have a higher error rate compared to other sequencing technologies; however, implementing a double error correction scheme in poreFUME we achieve accuracies above 97%, which enables reliable resistance gene annotation and comparable results to that of PacBio SMRT sequencing. In this study both sequencing platforms enabled the reliable identification of 26 unique antibiotic resistance genes. This, along with the rapid turnaround time of the poreFUME workflow, suggests that it could be applied as a possible resistome monitoring tool.

Only 39 % of the nanopore 2D reads had their barcodes successfully demultiplexed in this study. Improvements to the protocol can be made by making use of barcodes with a larger editing distance. In accordance, the currently used PacBio barcodes are

229 deprecated and replaced by a set with a larger editing distance, which allows for better
230 separation and a higher barcode identification rate. However, even the 61 % loss due
231 to barcode demultiplexing does not hamper downstream resistome analysis using
232 poreFUME.
233
234 In conclusion, the poreFUME pipeline provides a promising alternative to other next-
235 generation sequencing alternatives [6, 15] and can be used to rapidly profile the
236 resistome of both environmental and gut microbial communities [4–6]. We foresee
237 that rapid resistome profiling tools such as poreFUME could aid the implementation
238 of personalized antibiotic treatment in high risk patients.
239

240 Material and Methods

241 Experimental work

242 Ethics statement

243 Ethical approval for this study was obtained from the institutional review board of the
244 University Medical Center Utrecht (Utrecht, The Netherlands). During hospitalization
245 informed consent was waived. The collection of fecal samples after hospitalization
246 was done with the subject written consent.
247

248 Sample collection

249 Longitudinal fecal samples were collected from a human adult who received ICU care
250 at the Utrecht University Hospital in Netherland. The subject was a patient who after
251 surgical intervention was admitted to ICU. Five longitudinal samples were collected
252 upon admission, during ICU stay and 8 months after hospitalization. During the
253 recovery at ICU, the patient received antibiotics from at least the cephalosporin group

254 (beta-lactam) and SDD (Selective Digestive Decontamination), which included the
255 aminoglycoside (tobramycin) and polymyxin (colistin) antibiotic class.

256 **DNA extraction**

257 DNA was obtained from Utrecht University Hospital in the Netherlands. The DNA
258 extraction method was described previously [28].

259 **Construction of metagenomic libraries for functional selections**

260 Construction of metagenomic libraries was done following the protocol [23] with
261 slight modifications. DNA was sheared using a Covaris shearer to an average size of 2
262 kb. DNA was blunt-ended and phosphorylated using an End-Repair kit (Epicentre,
263 USA). Sheared DNA (138 µl) was mixed with 20 µl 10X End Repair buffer, 20 µl 2.5
264 mM dNTP, 20 µl 10 mM ATP and 2 µl of End-It enzyme. After incubation at 22 °C
265 for 55 min, the end-repair reaction was heat inactivated at 70 °C for 20 min. End-
266 repaired DNA was size selected by electrophoresis. Agarose gel slices selected from
267 the size range 0.5 – 5 kb were purified using the Gel Purification Kit (Fermentas). Gel
268 purified DNA was ligated into vector pZE21-MCS-1 [29] using Fast-link DNA ligase
269 (Epicentre). For this purpose, the concentration of gel-purified and end-repaired DNA
270 insert was adjusted to 200 ng/µl. Ligation reaction was set up with 2.5 µl of DNA
271 inserts (200 ng/µl), 0.5 µl 10X Ligation buffer, 0.25 µl 10mM ATP, 0.25 µl dH_2O, 0.5
272 µl HincII cut pZE21-MCS-1 vector (100 ng/µl). The ligation mixture was incubated at
273 22 °C for 16 h and finally heat inactivated at 70 °C for 20 min. Three µl of ligation
274 reaction was electroporated into 50 µl electrocompetent *Escherichia coli* Top10 cells
275 (Invitrogen). After electroporation in a 2 mm cuvette (2000 V, 25 µF, 200R), cells
276 were recovered in 1 ml SOC medium for 1 h at 37 °C. Determination of the
277 transformation efficiency was done by plating out 1 µl and 0.01 µl of recovered cells
278 onto LB agar plates containing 50 µg/ml kanamycin (pZE21-MCS-1 vector contains a
279 selectable marker for kanamycin resistance) [29]. Colony forming units (CFU) were

280 counted after overnight incubation at 37 °C. For each library, the insert size
281 distribution was estimated by gel electrophoresis of the PCR products obtained by
282 amplifying the insert using primers flanking the HincII site of the multiple cloning
283 site of the pZE21-MCS-1 vector (>pZE21_81_104_57C and pZE21_151_174rc_58C;
284 Supplementary table 4) [23].
285 The size of each of the metagenomic libraries for functional selection was determined
286 by multiplying the average PCR based insert size with the number of colony forming
287 units (CFU). The size of the 5 metagenomic libraries for functional selection is listed
288 in Supplementary table 1. The rest of the recovered cells after transformation was
289 inoculated into 10 ml of LB broth supplemented with 50 µg/ml kanamycin and grown
290 overnight at 37 °C, 180 rpm. The overnight cultures were stored with 15 % glycerol at
291 -80 °C.

292 **Functional selection of antibiotic resistance clones**

293 The overnight cultures grown and stored at -80 °C allowed each clone after
294 transformation to amplify (e.g. total cell count would increase from $5x10^5$ CFU
295 containing the plasmid per ml to $5x10^8$ CFU/ml after overnight incubation and storage
296 at -80°C). Resulting amplification of the particular clone in the library was taken
297 resolved by plating each library approximately 100X coverage. That is, each unique
298 clone in the library was screened by plating out approximately 100 copies. For each
299 library, clones carrying antibiotic resistance determinants were selected by plating
300 onto solid LB agar supplemented with one of the seven antibiotics: tobramycin,
301 spectinomycin, ampicillin, cefotaxime, azithromycin, tetracycline or fosfomycin at
302 concentrations that were inhibiting the wild type strain (Supplementary table 2). The
303 CFU was determined after overnight incubation at 37 °C (Supplementary table 2).

304 **Sequencing of antibiotic resistance clones**

305 From each antibiotic plate, a representative number of clones were selected for

306 sequencing and further analysis of antibiotic resistant genes. Singe colonies selected
307 on antibiotic resistance plates were picked up into 96-well plates (each 96 well
308 contained 200 µl LB broth supplemented with 50 µg/ml kanamycin). The selected
309 clones were grown overnight at 37 °C. The clones were transferred using a 96-pin
310 replicator into new 96-well plates and onto squared LB agar plates supplemented with
311 50 µg/ml kanamycin. Singe clones from 96-well plates were Sanger sequenced using
312 primers listed in table Supplementary table 4 by Beckman Genomics, UK.
313
314 The clones from the individual square agar plates were collected by adding 5 ml dH_20
315 and scraped off with an L-shaped cell scraper. The washing step was repeated twice to
316 remove all the cells from the plate. The bacterial cells were then pelleted by
317 centrifugation at 5.000 rpm x g for 10 min. The supernatant was discarded and the
318 pellet was dissolved in 10 ml of dH_2O. Two ml of the collected bacterial cells was
319 used for plasmid extractions with the Plasmid Mini Kit (Invitrogen). The rest of the
320 cells were heat inactivated at 95 °C for 10 min and stored as raw bacterial cell pellet.
321 For nanopore and PacBio sequencing, primers were synthetized that amplify the
322 common region on pZE21-MCS- together with the specific barcodes from PacBio
323 (Supplementary table 5). One ng of DNA or 1 µl of raw bacterial cell pellet was
324 amplified by PCR. Amplified and barcoded DNA was size selected by
325 electrophoresis. Agarose gel slices selected from the size range 1 – 5 kb were purified
326 using Gel Purification Kit (Fermentas). In total 39 barcodes (1 and 11-48) were
327 multiplexed.

328 **Nanopore sequencing library preparation**

329 The nanopore sequencing library B was prepared during poreCamp as briefly
330 described below. DNA QC was performed using Qubit dsDNA High Sensitivity

331 Assay Kit (Q32851, Thermo Fisher Scientific, USA) and 2200 TapeStation
332 (G2964AA, Agilent, USA). Sequencing library preparation was carried out with
333 Nanopore Genomic Sequencing Kit SQK-MAP006 (Oxford Nanopore, UK) and a
334 PCR free 'native barcoding' kit according to the manufacturer's protocol. The
335 NEBNext Ultra II End Repair/dA Tailing module (E7546S, NEB, USA) was used to
336 prepare 1000 ng of the functionally selected DNA. End-prepared DNA was ligated
337 with native barcode adapters NB04 from Oxford Nanopore using Blunt/TA Ligase
338 Master Mix (M0367S, NEB, USA). The resulting DNA was pooled with 8 other
339 unrelated barcoded libraries by equivalent weight. The pooled sample was mixed with
340 the 'Native Barcoding Adapter Mix (BAM)' and 'Native Barcoding Hairpin Adapter
341 (BHP)' together with Blunt/TA Ligase Master Mix (M0367S, NEB, USA), and after
342 incubation HP tether was added. The reaction mixture was cleaned up using
343 prewashed Dynabeads MyOne Streptavidin C1 (65001; Thermo Fisher Scientific,
344 USA).
345 The sequencing library A was prepared using the same protocol as library B, but the
346 barcoding and pooling steps were omitted.
347

348 **Nanopore sequencing**
349 The MinION was primed twice for 10 minutes with 500 µl priming solution (250 µl
350 nuclease free water, 237 µl 2x Running Buffer, 13 µl Fuel Mix). For sequencing, 6 µl
351 library was mixed with 65 µl nuclease free water, 75 µl 2x Running Buffer and 4 µl
352 Fuel Mix (SQK-MAP006, Oxford Nanopore, UK) and immediately loaded to a
353 MinION. The 'SQK-MAP006 Scripts for Yield Monitoring Switch, Bias-Voltage Re-
354 mux Tuning & Pore Shepherding' by John Tyson (personal communication) were
355 used in the MinKNOW software to sequence the library.

356 ## Data analysis

357 ### Nanopore data processing

358 The sequencing data was basecalled using Metrichor. The Metrichor workflow for
359 sequencing library A included additional native barcode demultiplexing.
360 Poretools[30] was used to extract 2D reads using the *poretools fasta --type 2D*
361 command. Next the 2D reads were analyzed using poreFUME.

362 ### poreFUME nanopore sequence analysis

363 The poreFUME pipeline consists of three steps. First, the reads are demultiplexed on
364 barcode using the Smith-Waterman algorithm[31]. Barcodes are detected within 60
365 (Library A) or 120 (Library B) basepairs of the read ends. Barcode alignment was
366 scored using +2.7 for match, -4.5 for mismatch, -4.7 gap opening and -1.6 for gap
367 extension. A score threshold of >58 was used for the combined score of the
368 asymmetric barcodes. Second, the demultiplexed reads were error corrected using the
369 original nanocorrect protocol [21]. The original nanocorrect protocol implements a
370 minimum read coverage of 3x, to ensure that only high-quality data will be outputted.
371 Since we were also interested maximizing sequence diversity, we adjusted the
372 minimum coverage to 1x in the second round of nanocorrect by modifying the
373 *min_coverage* parameter from 3 to 1. In the last step of poreFUME the error
374 corrected reads were mapped against the CARD database[22] using blastn[32]
375 (version 2.4.0) with the parameters *max_hsps* 1 and *max_target_seqs* 1000. Closely
376 related genes such as *TEM, CTX, MIR* and *SRT* (ie. *SRT-1* and *SRT-2*) were masked
377 and only reported as such (ie. *SRT*). For each individual read the BLAST hits were
378 sorted by bitscore and the highest scoring CARD hit on each segment was kept. For
379 successful CARD gene calling two threshold were set: a sequence identity of >80%
380 and a >50% coverage of the original gene in the CARD database.

381 **Sanger sequence data analysis**

382 The Sanger sequencing resulted in 770 'forward' and 779 'reverse' sequencing reads.
383 Sanger DNA sequences were imported to CLC Genomic Workbench (version 7.6.4).
384 Sequences were vector and quality trimmed (Q 0.01) and assembled using the
385 'Assemble Sequences' module. Contigs with a length of <500 basepairs were omitted
386 from further analysis.

387 **PacBio data analysis**

388 PacBio sequences were obtained from the Norwegian Sequencing Centre at the
389 University of Oslo in two flowcells on the Pacific Biosciences RS II instrument using
390 P6-C4 chemistry. The metrics for the total set are listed in Supplementary table 6. Raw
391 PacBio data from the flowcells was analyzed with PacBio SMRT® Portal version
392 2.3.0 and reads were extracted using the RS_ReadsOfInsert protocol (version 2.3.0).
393 The RS_ReadsOfInsert protocol was run with a minimum predicted accuracy of 99,
394 and minimum read length of insert length of 100 bp. Additionally paired-end barcode
395 detection was performed using the pacbio_barcodes_paired scheme containing 48
396 unique barcode pairs. A minimum barcode score of 15 was used in both cells. The
397 extracted reads of insert were grouped by individual barcode and exported in the
398 fastq. The final yield is reported in Supplementary table 5.

399 PacBio reads were collapsed with Pbdagcon
400 (https://github.com/PacificBiosciences/pbdagcon, version f19aed1) using dazcon with
401 the flags *--only-proper-overlaps* and *--coverage-sort* and parameter *--min-coverage*
402 0.

Declarations

Competing financial interests

EvdH and AK are both member of the Oxford Nanopore Technologies MAP (Minion Access Program) and have received reagents free of charge as part of the MinION Access Program.

Availability of data and materials

The source code for poreFUME is available at https://github.com/EvdH0/poreFUME and the full analysis of the data is available at https://github.com/EvdH0/poreFUME_paper/. The PacBio and nanopore sequence data is deposited at ENA with project code PRJEB14994.

Acknowledgement

This research was funded by the EU FP7-Health Program Evotar (282004), The Novo Nordisk Foundation and The Lundbeck Foundation. Additionally this work was supported by the European Union Seventh Framework Programma – INT FP/7/2012/317058 to EvdH. MMHE acknowledge the help and assistance of Ali Syed and other members of computerome, Danish National Supercomputer for Life Sciences, in using the HPC facilities. Library B was prepared during the porecamp MinION workshop in Birmingham December 2015, all participants and organizers (Nick Loman, Matt Loose, Mick Watson, Josh Quick, John Tyson and Justin O'Grady) are thanked, especially Kathrin Lang for help with writing up of the sequencing protocol. The PacBio sequencing service was provided by the Norwegian Sequencing Centre (www.sequencing.uio.no), a national technology platform hosted by the University of Oslo and supported by the "Functional Genomics" and "Infrastructure" programs of the Research Council of Norway and the Southeastern Regional Health Authorities.

429 **Author contributions**

430 EvdH and MOAS conceived the study. WvS obtained IRB approval and organized
431 fecal sample collection. LI designed the experiments, carried out the metagenomic
432 library construction, functional selections and obtained Sanger sequencing data.
433 MMHE provided input on the poreFUME pipeline and provide assistance with an
434 early prototype. EvdH carried out the nanopore sequencing library preparation
435 together with AK. EvdH ran the sequencing experiments and wrote the poreFUME
436 code. EvdH wrote the manuscript with input from the other authors.

437 ## References

438 1. O'Neill J: **Tackling Drug-Resistant Infections Globally : Final Report and**
439 **Recommendations**. 2016(May).

440 2. WHO: **Antimicrobial resistance.** *Bull World Health Organ* 2014, **61**:383–94.

441 3. de Kraker MEA, Davey PG, Grundmann H: **Mortality and hospital stay**
442 **associated with resistant Staphylococcus aureus and Escherichia coli bacteremia:**
443 **Estimating the burden of antibiotic resistance in Europe**. *PLoS Med* 2011, **8**.

444 4. Pehrsson EC, Tsukayama P, Patel S, Mejía-Bautista M, Sosa-Soto G, Navarrete
445 KM, Calderon M, Cabrera L, Hoyos-Arango W, Bertoli MT, Berg DE, Gilman RH,
446 Dantas G: **Interconnected microbiomes and resistomes in low-income human**
447 **habitats**. *Nature* 2016, **533**:212–216.

448 5. Dantas G, Sommer MO a, Oluwasegun RD, Church GM: **Bacteria subsisting on**
449 **antibiotics.** *Science* 2008, **320**:100–3.

450 6. Forsberg KJ, Reyes A, Wang B, Selleck EM, Sommer MO a, Dantas G: **The**
451 **Shared Antibiotic Resistome of Soil Bacteria and Human Pathogens**. *Science*
452 2012:1107–1111.

453 7. Sommer MOA, Dantas G: **Antibiotics and the resistant microbiome**. *Curr Opin*
454 *Microbiol* 2011, **14**:556–563.

455 8. Gibson MK, Wang B, Ahmadi S, Burnham C-AD, Tarr PI, Warner BB, Dantas G:
456 **Developmental dynamics of the preterm infant gut microbiota and antibiotic**
457 **resistome**. *Nat Microbiol* 2016(March):16024.

458 9. Forslund K, Sunagawa S, Coelho LP, Bork P: **Metagenomic insights into the**
459 **human gut resistome and the forces that shape it**. *BioEssays* 2014, **36**:316–329.

460 10. Handelsman J, Rondon MR, Brady SF, Clardy J, Goodman RM: **Molecular**
461 **biological access to the chemistry of unknown soil microbes: a new frontier for**
462 **natural products.** *Chem Biol* 1998, **5**:R245–9.

463 11. Rondon MR, August PR, Bettermann AD, Brady SF, Grossman TH, Liles MR,
464 Kara A, Lynch BA, Macneil IA, Minor C, Tiong CL, Gilman M, Osburne MS,
465 Handelsman J, Goodman RM, Rondon MR, August PR, Bettermann AD, Brady SF,
466 Grossman TH, Liles MR, Loiacono KA, Lynch BA, Macneil IA, Minor C, Tiong CL,
467 Gilman M, Osburne MS, Clardy J, Handelsman J: **Cloning the Soil Metagenome : a**
468 **Strategy for Accessing the Genetic and Functional Diversity of Uncultured**
469 **Microorganisms Cloning the Soil Metagenome : a Strategy for Accessing the**
470 **Genetic and Functional Diversity of Uncultured Microorganisms**. *Appl Environ*
471 *Microbiol* 2000, **66**:2541–2547.

472 12. MacNeil IA, Tiong CL, Minor C, August PR, Grossman TH, Loiacono KA,
473 Lynch BA, Phillips T, Narula S, Sundaramoorthi R, Tyler A, Aldredge T, Long H,
474 Gilman M, Holt D, Osburne MS: **Expression and isolation of antimicrobial small**
475 **molecules from soil DNA libraries.** *J Mol Microbiol Biotechnol* 2001, **3**:301–8.

476 13. Iqbal H a;, Craig JW, Brady SF: **Antibacterial enzymes from the functional**

477 **screening of metagenomic libraries hosted in Ralstonia metallidurans**. *FEMS*
478 *Microbiol Lett* 2014, **354**:19–26.

479 14. Forsberg KJ, Patel S, Gibson MK, Lauber CL, Knight R, Fierer N, Dantas G:
480 **Bacterial phylogeny structures soil resistomes across habitats.** *Nature* 2014,
481 **509**:612–616.

482 15. Wichmann F, Udikovic-Kolic N, Andrew S, Handelsman J: **Diverse antibiotic**
483 **resistance genes in dairy cow manure**. *MBio* 2014, **5**.

484 16. Ashton P, Nair S, Dallman T, Rubino S, Rabsch W, Mwaigwisya S, Wain J,
485 O'Grady J: **MinION nanopore sequencing identifies the position and structure of**
486 **a bacterial antibiotic resistance island**. *Nat Biotechnol* 2014, **33**:296–300.

487 17. Urban JM, Bliss J, Lawrence CE, Gerbi SA: **Sequencing ultra-long DNA**
488 **molecules with the Oxford Nanopore MinION**. *bioRxiv* 2015:019281.

489 18. Judge K, Harris SR, Reuter S, Parkhill J, Peacock SJ: **Early insights into the**
490 **potential of the Oxford Nanopore MinION for the detection of antimicrobial**
491 **resistance genes**. *J Antimicrob Chemother* 2015, **70**:2775–2778.

492 19. Turton JF, Doumith M, Hopkins KL, Perry C, Meunier D, Woodford N: **Clonal**
493 **expansion of Escherichia coli ST38 carrying chromosomally-integrated OXA-48**
494 **carbapenemase gene.** *J Med Microbiol* 2016, **38**:538–546.

495 20. Bradley P, Gordon NC, Walker TM, Dunn L, Heys S, Huang B, Earle S,
496 Pankhurst LJ, Anson L, de Cesare M, Piazza P, Votintseva AA, Golubchik T, Wilson
497 DJ, Wyllie DH, Diel R, Niemann S, Feuerriegel S, Kohl TA, Ismail N, Omar S V,
498 Smith EG, Buck D, McVean G, Walker AS, Peto T, Crook D, Iqbal Z: **Rapid**
499 **antibiotic resistance predictions from genome sequence data for S. aureus and**
500 **M. tuberculosis.** *Nat Commun* 2015, **6**:018564.

501 21. Loman NJ, Quick J, Simpson JT: **A complete bacterial genome assembled de**
502 **novo using only nanopore sequencing data**. *Nat Methods* 2015, **12**:733–735.

503 22. McArthur AG, Waglechner N, Nizam F, Yan A, Azad MA, Baylay AJ, Bhullar K,
504 Canova MJ, De Pascale G, Ejim L, Kalan L, King AM, Koteva K, Morar M, Mulvey
505 MR, O'Brien JS, Pawlowski AC, Piddock LJ V, Spanogiannopoulos P, Sutherland
506 AD, Tang I, Taylor PL, Thaker M, Wang W, Yan M, Yu T, Wright GD: **The**
507 **comprehensive antibiotic resistance database**. *Antimicrob Agents Chemother* 2013,
508 **57**:3348–3357.

509 23. Sommer MO a, Dantas G, Church GM: **Functional characterization of the**
510 **antibiotic resistance reservoir in the human microflora.** *Science* 2009, **325**:1128–
511 31.

512 24. Myers G: *14th International Workshop, WABI 2014, Wroclaw, Poland, September*
513 *8-10, 2014. Proceedings*. *Volume 8701*. Springer-Verlag Berlin Heidelberg; 2014.

514 25. Lee C, Grasso C, Sharlow MF: **Multiple sequence alignment using partial**
515 **order graphs**. *Bioinformatics* 2002, **18**:452–464.

516 26. Martínez JL, Coque TM, Baquero F: **What is a resistance gene? Ranking risk in**
517 **resistomes**. *Nat Rev Microbiol* 2015, **13**:116–123.

518 27. Wang J, Stephan R, Power K, Yan Q, Hachler H, Fanning S: **Nucleotide**
519 **sequences of 16 transmissible plasmids identified in nine multidrug-resistant**
520 **Escherichia coli isolates expressing an ESBL phenotype isolated from food-**
521 **producing animals and healthy humans**. *J Antimicrob Chemother* 2014, **69**:2658–
522 2668.

523 28. Buelow E, Gonzalez TB, Versluis D, Oostdijk EAN, Ogilvie LA, van Mourik
524 MSM, Oosterink E, van Passel MWJ, Smidt H, D'Andrea MM, de Been M, Jones B

525 V, Willems RJL, Bonten MJM, van Schaik W: **Effects of selective digestive**
526 **decontamination (SDD) on the gut resistome.** *J Antimicrob Chemother* 2014,
527 **69**:2215–23.

528 29. Lutz R, Bujard H: **Independent and tight regulation of transcriptional units in**
529 **Escherichia coli via the LacR/O, the TetR/O and AraC/I1-I2 regulatory**
530 **elements.** *Nucleic Acids Res* 1997, **25**:1203–10.

531 30. Loman NJ, Quinlan AR: **Poretools: a toolkit for analyzing nanopore sequence**
532 **data**. *Bioinformatics* 2014, **30**:3399–3401.

533 31. Smith TF, Waterman MS: **Identification of Common Molecular Subsequences**.
534 *J Mol Biol* 1981, **147**:195–197.

535 32. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden
536 TL: **BLAST+: architecture and applications.** *BMC Bioinformatics* 2009, **10**:421.

537

538

539 # Supplementary information

540

541 **Supplementary table 1: Library size in basepair of the constructed metagenomic libraries**

Sample	Size (bp)
120A	288120000
120B	546040000
120C	881280000
120D	574560000
120E	479360000

542 **Supplementary table 2: inhibitory concentrations of antibiotics used and the number of clones per agar**

Antibiotic	Abbreviation	Concentration (µg/ml)	Sample (n clones / agar plate)					
			120A	120B	120C	120D	120E	total
Tobramycin	TOB	6	121	216	480	950	240	2007
Spectinomycin	SPC	32	220	180	640	360	184	1584
Ampicillin	AMP	64	156	180	140	524	216	1216
Cefotaxime	CFT	2	48	58	14	6	139	256
Azithromycin	AZY	16	26	156	154	640	36	1012
Tetracycline	TET	6	6	142	100	71	15	334
Fosfomycin	FOS	128	58	124	288	111	52	633

543

544 **Supplementary table 3: Statistics of the Sanger, PacBio and two nanopore sequencing sets**

sample	workflow	number of entities	mean length [bp]	yield [Mbase]	mean sequence identity of entities to raw Sanger reads [%]	mean sequence identity of hits to CARD database [%]
Sanger	raw	1,568	952	1.5		98.76
	assembled	111	1,532	0.2	99.96	98.87
PacBio	raw	68,144	1,370	93.4	99.77	98.64
	assembled	3,086	1,626	5.0	99.28	97.83
nanopore library A	raw 2D	62,890	1,513	95.1	85.93	85.80
	after debarcoding	24,126	1,440	34.7	86.81	86.41
	after nanocorrect round 1	12,820	1,541	19.8	96.88	96.19
	after nanocorrect round 2	12,820	1,540	19.7	97.76	97.08
nanopore library B	raw 2D	4,959	1,587	7.9	86.15	85.65
	after debarcoding	3,361	1,426	4.8	86.38	85.80
	after nanocorrect round 1	2,392	1,444	3.5	96.81	96.34
	after nanocorrect round 2	2,392	1,441	3.4	97.59	97.19

545

546 **Supplementary table 4: Primers used in this study for Sanger sequencing**

Name	Sequence (5'- 3')	Reference
pZE21_81_104_57C	GAATTCATTAAAGAGGAGAAAGGT	[23]
pZE21_151_174rc_58C	TTTCGTTTTATTTGATGCCTCTAG	[23]

547

548 **Supplementary table 5: Primers used to barcode the sample for PacBio and nanopore sequencing**

549 Attached csv file

550

551 **Supplementary table 6: Statistics of the two sequencing cells of the filtered (quality >99% and barcode**
552 **demultiplexed) PacBio reads as reported by SMRT Portal. Both PacBio cells were used in the analysis.**

sample	reads	mean read length [bp]	mean read quality
PacBio cell I	31,554	1,439	0.9980
PacBio cell II	36,590	1,384	0.9979
total	68,144		

553


Sanger raw
number of Sanger reads
500
400
300
200
100
0
PacBio raw
number of PacBio reads
14000
12000
10000
8000
6000
4000
2000
0
nanopore lib. B:
2D reads
number of 2D nanopore reads
1200
1000
800
600
400
200
0
350
300
250
200
150
100
50
0
input DNA sample intensity [FU]
nanopore lib. A: 2D reads
number of 2D nanopore reads
14000
12000
10000
8000
6000
4000
2000
0
1,000
10,000
size [bp]

554

555 **Supplementary Figure 1: Read length distribution of the control Sanger (purple) data with a mean of 952**
556 **bp and PacBio (blue) data with a mean read length of 1370 bp. The 2D read length of nanopore library A**
557 **(orange) with a mean of 1587 bp is overlaid with the DNA input sample intensity (red) measured using a**
558 **TapeStation showing agreement between the length distribution. Nanopore library B has a mean read**
559 **length of 1513 bp.**


Sanger raw mean:98.76
Sanger assembled mean:99.96%
Sanger assembled mean:98.87
PacBio raw mean:99.77%
PacBio raw mean:98.64
PacBio assembled mean:99.28%
PacBio assembled mean:97.83
nanopore lib. A: 2D reads mean:85.93%
nanopore lib. A: 2D reads mean:85.8
nanopore lib. A: after debarcoding mean:86.81%
nanopore lib. A: after debarcoding mean:86.41
nanopore lib. A: after nanocorrect round 1 mean:96.88%
nanopore lib. A: after nanocorrect round 1 mean:96.19
nanopore lib. A: after nanocorrect round 2 mean:97.76%
nanopore lib. A: after nanocorrect round 2 mean:97.08
nanopore lib. B: 2D reads mean:86.15%
nanopore lib. B: 2D reads mean:85.65
nanopore lib. B: after debarcoding mean:86.38%
nanopore lib. B: after debarcoding mean:85.8
nanopore lib. B: after nanocorrect round 1 mean:96.8%
nanopore lib. B: after nanocorrect round 1 mean:96.34
nanopore lib. B: after nanocorrect round 2 mean:97.59%
nanopore lib. B: after nanocorrect round 2 mean:97.19
no. of reads
no. of CARD hits
sequence identity to Sanger [%]
sequence identity to CARD database [%]

560

561 **Supplementary Figure 2: Sequence identity of the Sanger (purple), PacBio (blue) , nanopore library A**
562 **(orange) and nanopore library B (green) dataset measured against the Sanger dataset in the left column**
563 **(with >500 bp in alignment length). The sequence identity of the highest scoring hits (with a gene coverage**
564 **requirement of >50%) in the CARD database are shown in the right column.**

565


AAC(6')-Ic
nanopore:557
PacBio:85
AAC(6')-Ie-APH(2")-Ia
nanopore:71
PacBio:35
AAC(6')-Ii
nanopore:65
PacBio:27
AAC(6')-Ip
nanopore:840
PacBio:198
ACT-37
nanopore:12
APH(2")-IIa
nanopore:813
PacBio:204
APH(3')-IIIa
nanopore:282
PacBio:55
CMY-15
nanopore:10
PacBio:14
CMY-38
nanopore:9
PacBio:24
CTX
nanopore:259
PacBio:90
CblA-1
nanopore:2472
PacBio:141
ErmB
nanopore:833
PacBio:196
ErmF
nanopore:210
PacBio:105
ErmG
nanopore:55
PacBio:25
ErmX
nanopore:149
PacBio:57
MIR
nanopore:55
PacBio:1
SRT
nanopore:1
PacBio:10
TEM
nanopore:1558
PacBio:199
aadA
nanopore:881
PacBio:127
dfrA1
nanopore:274
PacBio:36
mel
nanopore:47
PacBio:22
sat-1
nanopore:534
PacBio:69
sat-4
nanopore:104
PacBio:39
tetC
nanopore:41
PacBio:22
tetL
nanopore:1
PacBio:15
tetM
nanopore:19
PacBio:20
tetO
nanopore:41
PacBio:78
tetQ
nanopore:20
PacBio:8
tetW
nanopore:181
PacBio:77
tetX
nanopore:42
PacBio:31
number of hits
sequence identity to CARD database [%]

566

567 **Supplementary Figure 3: Overview of unique antibiotic resistance genes of the CARD database that are**
568 **found in the nanopore library A (green) and PacBio set (blue). The number of reads over the sequence**
569 **identity [%] to the respective gene in the CARD database is shown. In the legend box the total number of**
570 **reads for each dataset is shown.**

571
572